New sexual dysfunction risks linked to Merck's baldness, BPH drugs
This article was originally published in Scrip
Executive Summary
The US labelling for Merck's finasteride, a 5 alpha-reductase inhibitor, which is sold as a 1mg formulation as Propecia to treat mild-to-moderate male pattern hair loss, and at the 5mg dose as Proscar to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate, is being updated to note additional adverse sexual events linked to the drug after the medication is stopped.